Aprea Therapeutics Closes Oversubscribed $30 Mln Private Placement; Stock Down

(RTTNews) - Aprea Therapeutics, Inc. (APRE), a clinical-stage precision medicine oncology company, on Wednesday announced the closing of its previously announced oversubscribed $30 million private placement financing on March 31, 2026.

The company intends to use the upfront net proceeds for general corporate purposes and for research and development expenses. The private placement was led by Soleus Capital.

The company's lead product candidates include APR-1051, in a Phase 1 clinical trial for the treatment of patients with advanced solid tumours, and ATRN-119, in Phase 1/2a clinical trials for solid tumour indications.

Meanwhile, on Tuesday, Wedbush analyst Robert Driscoll reaffirmed an Outperform rating and a 12-month price Target of $7 for Aprea Therapeutics.

This follows the highlighted positive emerging clinical activity by Aprea for APR-1051 in the ongoing Phase 1 trial in patients with advanced solid tumours harbouring cancer-associated genetic alterations, dubbed the ACESOT-1051 trial.

Commenting on the clinical trial updates of APR-1051, analyst Robert Driscoll said, "We look forward to additional updates in the second quarter of 2026".

As of December 31, 2025, Aprea reported cash and cash equivalents of $14.6 million, and, along with the proceeds from the recent private placement in January 2026, projected a cash runway through the first quarter of 2027 in its recent full-year 2025 financial report.

APRE has traded between $0.54 and $2.22 in the last year. APRE closed Wednesday's trade at $0.70, down 7.75%.

In the overnight market, APRE is further down 4.77% at $0.67.

For More Such Biotech and Pharmaceutical News, visit rttnews.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.